Total Payments
$2,349
2022 Payments
$214.35
Companies
24
Transactions
121
Medicare Patients
3,600
Medicare Billing
$577,038
Payment Breakdown by Category
Food & Beverage$2,051 (87.3%)
Education$298.08 (12.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,051 | 112 | 87.3% |
| Education | $298.08 | 9 | 12.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $467.99 | 17 | $0 (2017) |
| E.R. Squibb & Sons, L.L.C. | $295.48 | 19 | $0 (2017) |
| Novartis Pharmaceuticals Corporation | $188.74 | 11 | $0 (2017) |
| Genentech USA, Inc. | $173.13 | 11 | $0 (2017) |
| PFIZER INC. | $156.23 | 12 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $153.35 | 4 | $0 (2022) |
| Incyte Corporation | $136.60 | 8 | $0 (2017) |
| BTG International, Inc. | $119.70 | 1 | $0 (2022) |
| Bayer HealthCare Pharmaceuticals Inc. | $108.05 | 5 | $0 (2017) |
| Celgene Corporation | $100.05 | 4 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $214.35 | 2 | BTG International, Inc. ($119.70) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2018 | $60.72 | 4 | PFIZER INC. ($39.99) |
| 2017 | $2,062 | 114 | Amgen Inc. ($467.99) |
All Payment Transactions
121 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/14/2022 | BTG International, Inc. | VORAXAZE (Drug) | Food and Beverage | In-kind items and services | $119.70 | General |
| Category: Toxicity Antidote (Methotrexate Toxicity) | ||||||
| 09/29/2022 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $94.65 | General |
| Category: Oncology | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 11/27/2018 | PFIZER INC. | SUTENT (Drug), INLYTA, BAVENCIO | Food and Beverage | In-kind items and services | $15.35 | General |
| Category: ONCOLOGY;RESPIRATORY | ||||||
| 07/24/2018 | Otsuka America Pharmaceutical, Inc. | REXULTI (Drug) | Food and Beverage | In-kind items and services | $20.73 | General |
| Category: PSYCHIATRY | ||||||
| 05/08/2018 | PFIZER INC. | IBRANCE (Drug) | Education | In-kind items and services | $12.49 | General |
| Category: ONCOLOGY | ||||||
| 03/05/2018 | PFIZER INC. | SUTENT (Drug), INLYTA, BAVENCIO | Food and Beverage | In-kind items and services | $12.15 | General |
| Category: ONCOLOGY;RESPIRATORY | ||||||
| 11/26/2017 | PFIZER INC. | SUTENT (Drug), INLYTA, BAVENCIO | Food and Beverage | In-kind items and services | $16.05 | General |
| Category: ONCOLOGY;RESPIRATORY | ||||||
| 11/21/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $15.47 | General |
| Category: Oncology | ||||||
| 11/16/2017 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $13.68 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2017 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $8.55 | General |
| Category: Hematology/Oncology | ||||||
| 11/02/2017 | Amgen Inc. | Nplate (Biological), XGEVA | Food and Beverage | In-kind items and services | $18.75 | General |
| Category: Hematology | ||||||
| 11/01/2017 | Genentech USA, Inc. | TECENTRIQ (Biological) | Food and Beverage | In-kind items and services | $15.06 | General |
| Category: BioOncology | ||||||
| 10/31/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.67 | General |
| Category: Oncology | ||||||
| 10/30/2017 | GENZYME CORPORATION | JEVTANA (Drug) | Food and Beverage | In-kind items and services | $20.66 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2017 | Novartis Pharmaceuticals Corporation | AFINITOR (Drug), KISQALI, TYKERB | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: ONCOLOGY | ||||||
| 10/19/2017 | Janssen Pharmaceuticals, Inc | ZYTIGA (Drug) | Education | In-kind items and services | $13.07 | General |
| Category: Oncology | ||||||
| 10/16/2017 | Teva Pharmaceuticals USA, Inc. | BENDEKA (Drug) | Food and Beverage | In-kind items and services | $10.52 | General |
| Category: Oncology | ||||||
| 10/16/2017 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $2.50 | General |
| Category: Hematology/Oncology | ||||||
| 10/12/2017 | Celgene Corporation | Abraxane (Drug) | Food and Beverage | In-kind items and services | $21.05 | General |
| Category: Oncology | ||||||
| 10/12/2017 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $8.66 | General |
| Category: Hematology/Oncology | ||||||
| 10/11/2017 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $23.90 | General |
| Category: Oncology | ||||||
| 10/10/2017 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $14.15 | General |
| Category: ONCOLOGY | ||||||
| 10/02/2017 | Amgen Inc. | Neulasta (Biological), Vectibix | Food and Beverage | In-kind items and services | $21.88 | General |
| Category: Oncology | ||||||
| 09/28/2017 | AstraZeneca Pharmaceuticals LP | FASLODEX (Drug) | Food and Beverage | In-kind items and services | $19.84 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 930 | 1,384 | $328,231 | $160,820 |
| 2022 | 9 | 725 | 1,044 | $226,772 | $118,756 |
| 2021 | 12 | 936 | 1,422 | $280,097 | $163,747 |
| 2020 | 11 | 1,009 | 1,615 | $270,257 | $133,715 |
Total Patients
3,600
Total Services
5,465
Medicare Billing
$577,038
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 392 | 622 | $121,520 | $62,474 | 51.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 242 | 427 | $112,989 | $60,000 | 53.1% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 95 | 106 | $41,547 | $15,042 | 36.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 43 | 43 | $16,012 | $7,683 | 48.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 43 | 43 | $12,518 | $5,719 | 45.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 29 | 38 | $5,463 | $2,470 | 45.2% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 35 | 43 | $5,737 | $2,375 | 41.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 13 | 21 | $4,342 | $1,986 | 45.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 19 | 19 | $5,235 | $1,977 | 37.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 19 | 22 | $2,868 | $1,096 | 38.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 289 | 434 | $79,658 | $43,317 | 54.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 149 | 289 | $72,740 | $41,858 | 57.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 69 | 76 | $20,716 | $8,616 | 41.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 56 | 56 | $15,898 | $7,408 | 46.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 39 | 39 | $14,580 | $7,112 | 48.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 38 | 61 | $8,655 | $3,615 | 41.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 49 | 51 | $6,335 | $2,886 | 45.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 13 | 13 | $4,979 | $2,140 | 43.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 23 | 25 | $3,211 | $1,804 | 56.2% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 305 | 541 | $94,653 | $58,992 | 62.3% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 154 | 323 | $76,821 | $52,243 | 68.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 141 | 163 | $19,704 | $10,314 | 52.3% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 70 | 70 | $18,651 | $10,312 | 55.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 77 | 83 | $22,095 | $9,405 | 42.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 32 | 35 | $12,996 | $5,875 | 45.2% |
About Dr. John Smith, M.D
Dr. John Smith, M.D is a Hematology & Oncology healthcare provider based in Phillipsburg, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1275521361.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Smith, M.D has received a total of $2,349 in payments from pharmaceutical and medical device companies, with $214.35 received in 2022. These payments were reported across 121 transactions from 24 companies. The most common payment nature is "Food and Beverage" ($2,051).
As a Medicare-enrolled provider, Smith has provided services to 3,600 Medicare beneficiaries, totaling 5,465 services with total Medicare billing of $577,038. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Phillipsburg, NJ
- Active Since 10/12/2005
- Last Updated 02/20/2015
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1275521361
Products in Payments
- OPDIVO (Biological) $223.08
- Neulasta (Biological) $171.91
- AFINITOR (Drug) $157.16
- VORAXAZE (Drug) $119.70
- CALQUENCE (Drug) $94.65
- DARZALEX (Biological) $89.72
- Abraxane (Drug) $78.90
- Nplate (Biological) $77.16
- JAKAFI (Drug) $76.61
- IBRANCE (Drug) $64.83
- Stivarga (Drug) $63.06
- KEYTRUDA (Biological) $54.15
- Avastin (Biological) $49.56
- SUTENT (Drug) $49.31
- TECENTRIQ (Biological) $48.59
- Xofigo (Drug) $44.99
- ALIMTA (Drug) $42.19
- ELIQUIS (Drug) $41.85
- Perjeta (Biological) $41.75
- FASLODEX (Drug) $41.70
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.